We are live on
!
Find out more
N
Nuveen Portfolio holdings
AUM
$369B
1-Year Est. Return
31.66%
This Fund
S&P 500
This Quarter
Est. Return
-2.85%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$247B
AUM Growth
-$11.7B
(-4.5%)
Cap. Flow
-$1.08B
Cap. Flow
% of AUM
-0.44%
Top 10 Holdings %
Top 10 Hldgs %
21.96%
Holding
3,327
New
107
Increased
1,095
Reduced
1,938
Closed
58
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$3.11B |
| 2 |
iShares Russell 1000 Growth ETF
IWF
|
+$300M |
| 3 |
Baxter International
BAX
|
+$237M |
| 4 |
American Tower
AMT
|
+$196M |
| 5 |
UnitedHealth
UNH
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$343M |
| 2 |
Meta Platforms (Facebook)
META
|
+$300M |
| 3 |
Microsoft
MSFT
|
+$294M |
| 4 |
Salesforce
CRM
|
+$266M |
| 5 |
Match Group
MTCH
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.83% |
| 2 | Healthcare | 15.1% |
| 3 | Financials | 12.26% |
| 4 | Consumer Discretionary | 11.08% |
| 5 | Industrials | 8.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FIRY
2576
Firy Inc
FIRY
$163M
| $1.33M | ﹤0.01% |
65,203
-1,193
| -2% | -$33.6K |
|
2577
AerSale
ASLE
$279M
| $1.33M | ﹤0.01% |
71,761
-879
| -1% | -$16.3K |
|
2578
Kiniksa Pharmaceuticals
KNSA
$5.93B
| $1.33M | ﹤0.01% |
103,387
-4,767
| -4% | -$54.3K |
|
|
KNTE
2579
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $1.33M | ﹤0.01% |
111,053
-32
| -0% | -$419 |
|
2580
Archer Aviation
ACHR
$4.26B
| $1.32M | ﹤0.01% |
507,385
+64,501
| +15% | +$227K |
|
2581
Rush Enterprises Class B
RUSHB
$6.14B
| $1.32M | ﹤0.01% |
41,399
-1,686
| -4% | -$59.8K |
|
|
AMK
2582
DELISTED
AssetMark Financial Holdings, Inc.
AMK
| $1.32M | ﹤0.01% |
72,082
-71,444
| -50% | -$1.39M |
|
2583
Mercantile Bank Corp
MBWM
$1.05B
| $1.31M | ﹤0.01% |
44,205
-5
| -0% | -$167 |
|
2584
GCM Grosvenor
GCMG
$820M
| $1.3M | ﹤0.01% |
165,347
-10,287
| -6% | -$80.6K |
|
2585
Phathom Pharmaceuticals
PHAT
$692M
| $1.3M | ﹤0.01% |
117,579
+2,036
| +2% | +$19.4K |
|
|
HRT
2586
DELISTED
HireRight Holdings Corporation
HRT
| $1.3M | ﹤0.01% |
85,382
+25,316
| +42% | +$400K |
|
2587
Anika Therapeutics
ANIK
$287M
| $1.3M | ﹤0.01% |
54,713
-852
| -2% | -$19.6K |
|
2588
Axogen
AXGN
$2.5B
| $1.3M | ﹤0.01% |
108,926
-8,907
| -8% | -$89.1K |
|
2589
VSE Corp
VSEC
$6.12B
| $1.3M | ﹤0.01% |
36,684
-1,266
| -3% | -$49.2K |
|
|
BNFT
2590
DELISTED
Benefitfocus, Inc.
BNFT
| $1.3M | ﹤0.01% |
204,312
-4,680
| -2% | -$34.7K |
|
2591
Liberty Global Class C
LBTYK
$3.49B
| $1.3M | ﹤0.01% |
78,596
-252,902
| -76% | -$5.36M |
|
2592
Precigen
PGEN
$2.59B
| $1.29M | ﹤0.01% |
610,493
-39,474
| -6% | -$83.2K |
|
|
REVG
2593
DELISTED
REV Group
REVG
| $1.29M | ﹤0.01% |
117,177
-9,216
| -7% | -$106K |
|
2594
Turning Point Brands
TPB
$1.74B
| $1.29M | ﹤0.01% |
60,861
-817
| -1% | -$20.3K |
|
2595
Central Garden & Pet Co
CENT
$2.8B
| $1.29M | ﹤0.01% |
44,755
-429
| -0.9% | -$14.3K |
|
2596
Marcus Corp
MCS
$945M
| $1.29M | ﹤0.01% |
92,947
-1,678
| -2% | -$27K |
|
2597
NuScale Power
SMR
$4.03B
| $1.29M | ﹤0.01% |
110,482
+71,935
| +187% | +$945K |
|
2598
Stoke Therapeutics
STOK
$2.11B
| $1.29M | ﹤0.01% |
100,365
+26,329
| +36% | +$420K |
|
2599
Nuvation Bio
NUVB
$2.32B
| $1.29M | ﹤0.01% |
575,200
-12,492
| -2% | -$35.7K |
|
2600
Amplify Energy
AMPY
$166M
| $1.28M | ﹤0.01% |
195,215
-8,950
| -4% | -$60.9K |
|
Similar funds
VFT
Nuveen's Q3 2022 Portfolio in Review
As of Q3 2022, Nuveen held 3,327 positions worth $247B, down 4.5% from $259B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Trading was light in Q3 2022: portfolio turnover was 5%. Nuveen opened 107 new positions and exited 58, leaving the 3,327-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Healthcare and Financials.
- Nuveen's largest Q3 2022 buy was Alibaba: 1,014,906 shares worth $81.2M.
- Nuveen added most to Alnylam Pharmaceuticals in Q3 2022, an estimated $3.11B increase.
- Nuveen's biggest Q3 2022 reduction was Alphabet (Google) Class A, cutting an estimated $343M.
- Nuveen fully exited Atlassian in Q3 2022, selling an estimated $82.9M.
- Nuveen's ten largest holdings make up 22% of its $247B portfolio in Q3 2022.
- Nuveen opened 107 new positions and closed 58 in Q3 2022.
- Nuveen's portfolio value fell 4.5% quarter-over-quarter to $247B.
Based on Nuveen's 13F filing for Q3 2022, filed 14 Nov 2022.